Randomized, phase II study of two doses of pemetrexed as first-line chemotherapy for locally advanced or metastatic breast cancer (MBC): Clinical results and exploratory pharmacogenomic analysis.
Document type:
Meeting Abstract
Author(s):
Llombart-Cussac, A; Martin, M; Harbeck, N; Anghel, R; Eniu, A; Melemed, A; Clark, R; Simms, L; Kaiser, C; Ma, D